Mallinckrodt NDA for PENNSAID approved by FDA Mallinckrodt announced that the U.S. Food and Drug Administration has approved the New Drug Application for PENNSAID 2% w/w. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for use in the treatment of the pain of osteoarthritis of the knee(s). U.S. sales and marketing rights for PENNSAID 2% are licensed to Mallinckrodt by Nuvo Research Inc.
News For MNK From The Last 14 Days
Check below for free stories on MNK the last two weeks.